More than one million people each year are hospitalized due to Acute Decompensated Heart Failure (ADHF).1 ADHF results from chronic heart failure and/or cardiac, pulmonary, or renal dysfunction. The inpatient cost of ADHF care is extremely high – accounting for 60% of total heart failure expenditures.2
Unlike traditional approaches that only address symptoms, Cardionomic addresses the condition’s root cause of reduced contractility. The therapy uses neuromodulation to benignly increase contractility, thus improving cardiac output therefore increasing renal flow and end organ perfusion. Benignly increasing contractility decreases negative hormonal signaling, and improves in-hospital morbidity/mortality.
This breakthrough therapy is also expected to increase pharmacological tolerance at discharge, which will reduce costly readmission and extend life.
Spun off from Denali Medical II, a New Enterprise Associates (NEA) backed incubator, Cardionomic is funded by NEA, Greatbatch Medical and Cleveland Clinic Foundation.
1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update. A report from the American Heart Association. Circulation. 2010;121:e46–e215.
2. Michota FA Jr, Amin A. Bridging the gap between evidence and practice in acute decompensated heart failure management. J Hosp Med. 2008;3(suppl):S7-S15.
CAUTION: INVESTIGATIONAL DEVICE LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE.
©2021 Cardionomic, Inc. All Rights Reserved.